

Time to broaden the screening strategy for chronic hepatitis B virus infection beyond the emergency department



To the Editor:

It is with a great interest that we read the article by Llaneras *et al.*,¹ highlighting the role of the emergency department as a main healthcare gateway for HBV screening. HBV infection remains a significant global health problem and an important cause of cirrhosis, liver failure, and especially hepatocellular carcinoma. The World Health Organization (WHO) estimated that 296 million people were living with chronic hepatitis B infection in 2019, of whom only 30 million had been diagnosed.² In Australia, an estimated 222,559 people were living with HBV at the end of 2020, equating to approximately 1 in 100 people.³

Despite increases in the proportions of people receiving clinical care for HBV from 8.5% in 2016 to 10.7% in 2020⁴ and efforts to improve HBV screening, testing rates in Australia do not meet the WHO elimination targets for 2030. WHO targets include 90% diagnostic coverage and 80% treatment coverage among the eligible population with HBV infection.^{5,6} Unfortunately, it is estimated that 37% of people living with chronic hepatitis B in Australia remain undiagnosed and therefore they do not seek treatment, posing a risk of further HBV transmission in the unvaccinated population.⁷

In Australia, the national hepatitis B testing policy is limited to target populations with evidence of liver disease or risk factors for HBV infection, pregnant women, newborn infants, blood and tissue donors, and people working in the healthcare sector. However, this symptom- or risk-based testing is inadequate in general practice and captures only a fraction of the HBV-infected population. Therefore, a cost-effective universal screening strategy would increase diagnosis rates and thereby decrease the disease burden especially when combined with appropriate clinical management.

In this study, we performed a real-world service evaluation of routine HBV testing, looking to develop and expand on existing practice, which was already in place. The aim was first to explore the prevalence of HBV infection within populations accessing outpatient services beyond the emergency departments at Blacktown-Mount Drutt Hospital, Western Sydney, Australia. For this, electronic medical records of patients that attended antenatal, oncology, dialysis, and metabolic outpatient clinics between 2019 and 2021 (N = 11,006) were retrospectively reviewed for point-of-care HBsAg testing. Data on blood born virus status, FIB-4 (fibrosis-4), APRI (AST-to-platelet ratio index), demographic characteristics and risk factors were also collected.

Results demonstrate that the prevalence of HBsAg-positive individuals per 100,000 patients was 664 in antenatal, 1,392 in oncology, 2,797 in dialysis and 2,548 in metabolic clinics, respectively. This was significantly higher than the general NSW HBV notification rate in 2019 of 23.2 per 100,000 people

($p < 0.001$) (Table 1). Importantly, only 1.25% of the positive cases identified as Aboriginal and/or Torres Strait Islander. Among the four cohorts, 83.75% of HBV-positive patients had no known risk factors, whereas 3.75% had current or previous intravenous drug misuse. Approximately 12.5% were suspected to have had vertical transmission and 10% had a FIB-4 score of >1.75 and 8.75% had a APRI >0.5 , suggesting higher risk of liver fibrosis. The low estimated fibrosis levels also mean that these patients would not have been identified through liver fibrosis screening alone. Amongst those who were identified with HBV infection, only 35% were either referred to or followed up by specialists for monitoring of disease activity or treatment initiation, and only 7.5% had HBV DNA levels measured.

Our data demonstrate that HBV prevalence was significantly higher in all four cohorts than the estimated NSW notification rate for 2019.⁸ These figures may be even greater due to the impact of the COVID-19 pandemic (2019–2021) reducing HBV testing and diagnosis, as well as travel restrictions reducing migration between Australia and countries with higher hepatitis B prevalence.⁷ Therefore, to achieve WHO hepatitis B elimination targets in Australia, current testing practices should be expanded to include opportunistic screening of non-targeted populations.^{9,10} The WHO, state and national targets are unlikely to

Table 1. Prevalence of HBsAg-positive cases within populations accessing outpatient services (antenatal, oncology, dialysis and metabolic clinics) at Blacktown-Mount Drutt Hospital, Western Sydney, Australia.

	N = 11,006
HBV antigen positive	80 (0.73%)
Gender	
Female	71
Male	9
Age (mean)	36 [17,77]
Region of birth	
Australia/New Zealand	9
Oceania other	6
Asia	44
Europe	2
Africa	19
FIB-4	
Mild (<1.45)	72
Moderate ($1.45-3.25$)	4
Severe (>3.25)	4
Antenatal cohort (n = 9,789)	
HBsAg positive (per 100,000)	664
Oncology cohort (n = 287)	
HBsAg positive (per 100,000)	1,392
Dialysis cohort (n = 250)	
HBsAg positive (per 100,000)	2,797
Metabolic cohort (n = 156)	
HBsAg positive (per 100,000)	2,548

Received 3 February 2024; accepted 7 February 2024; available online 10 February 2024

be reached under current practice protocols and hence an intensified testing policy is needed.

Our study highlights the need to increase awareness and educate healthcare providers regarding appropriate HBV point-of-care testing and management, as 65% of patients had no post-test referral to appropriate care and approximately 92% did not have appropriate testing to assess the status of infection.

Financial support

The authors did not receive any financial support to produce this manuscript.

Conflict of interest

The authors of this study declare that they do not have any conflict of interest.

Please refer to the accompanying ICMJE disclosure forms for further details.

Authors' contributions

Study concept and design—E.K., and G.A.; Writing: original draft preparation—E.K.; Acquisition of data—A.B., Analyses and interpretation of data—E.K., A.B. and G.A.; Writing: review and editing—E.K., S.R. and G.A.; Supervision— S.R. and G.A. All authors approved the final version of the article, including the authorship.

References

- [1] Llaneras J, Ruiz-Cobo JC, Rando-Segura A, et al. Integrating viral hepatitis management into the emergency department: a further step towards viral hepatitis elimination. *JHEP Rep* 2023;6(1):100932. <https://doi.org/10.1016/j.jhepr.2023.100932>. 2023 Oct 12.
- [2] WHO Hepatitis B key facts. <https://www.who.int/news-room/fact-sheets/detail/hepatitis-b> Date: July 18, 2023, Date accessed: December 24, 2023.
- [3] King J, McManus H, Kwon A, et al. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2022. UNSW Sydney, Sydney, Australia: The Kirby Institute; 2022. <https://doi.org/10.26190/sx44-5366>.
- [4] McCulloch K, Romero N, MacLachlan JH, et al. National surveillance for hepatitis B indicators: measuring the progress towards the targets of the national hepatitis B strategy – annual report 2020. The Doherty Institute; 2021. WHO Collaborating Centre for Viral Hepatitis, https://www.doherty.edu.au/uploads/content_doc/National_Surveillance_for_Hepatitis_B_Indicators_2020_final.pdf.
- [5] McCulloch K, Romero N, MacLachlan J, et al. Modeling progress toward elimination of hepatitis B in Australia. *Hepatology* 2020;71(4):1170–1181. <https://doi.org/10.1002/hep.30899>.
- [6] Xiao Y, Howell J, van Gemert C, et al. Enhancing the hepatitis B care cascade in Australia: a cost-effectiveness model. *J Viral Hepat* 2020;27(5):526–536. <https://doi.org/10.1111/jvh.13252>.
- [7] MacLachlan J, Stewart S, Cowie B. Viral hepatitis mapping project: national report 2020. Viral hepatitis, and sexual health medicine. Sydney: Australasian Society for HIV; 2021; https://ashm.org.au/wp-content/uploads/2022/04/ASHM_ViralHepReport_2020_WEB_final.pdf. [Accessed 24 December 2023].
- [8] National cancer Control indicators, hepatitis B and C notification, published 24 June 2022, [https://nci.cancer australia.gov.au/prevention/hepatitis/hepatitis-b-and-hepatitis-c-notification#:~:text=Hepatitis%20B%20notifications&text=The%20notification%20rate%20for%20hepatitis,\(21.0%20cases%20per%20100%20C000\)](https://nci.cancer australia.gov.au/prevention/hepatitis/hepatitis-b-and-hepatitis-c-notification#:~:text=Hepatitis%20B%20notifications&text=The%20notification%20rate%20for%20hepatitis,(21.0%20cases%20per%20100%20C000)). (accessed 24 December 2023).
- [9] Allard NL, MacLachlan JH, Tran L, et al. Time for universal hepatitis B screening for Australian adults [published correction appears in *Med J Aust*. 2021 Sep 20;215(6):258]. *Med J Aust* 2021;215(3):103–105.e1. <https://doi.org/10.5694/mja2.51114>.
- [10] Xiao Y, Hellard ME, Thompson AJ, et al. The cost-effectiveness of universal hepatitis B screening for reaching WHO diagnosis targets in Australia by 2030. *Med J Aust* 2023;218(4):168–173. <https://doi.org/10.5694/mja2.51825>.

Eric Kalo^{1,2}

Asma Baig²

Scott Read^{1,2,3}

Golo Ahlenstiel^{1,2,3,*}

¹Blacktown Clinical School and Research Centre, School of Medicine, Western Sydney University, Blacktown, NSW 2148, Australia;

²Blacktown Hospital, Western Sydney Local Health District, Blacktown, NSW 2148, Australia;

³Storr Liver Centre, The Westmead Institute for Medical Research, University of Sydney, Westmead, NSW 2145, Australia

* Corresponding author. Address: Blacktown Clinical School and Research Centre, School of Medicine, Western Sydney University, 18 Blacktown Road, Blacktown, New South Wales, 2148, Australia.

E-mail address: g.ahlenstiel@westernsydney.edu.au (G. Ahlenstiel).